AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30278459 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 43
Study 27307305 — intervention group
Group type: EXPERIMENTAL
Intervention: broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7 days
Number of subjects: 16
Study 27307305 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 16
Study 27307305 — intervention group
Group type: EXPERIMENTAL
Intervention: broad-spectrum antibiotics
Number of subjects: 16
Study 26308780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention for medication adherence and blood pressure control (3-month duration)
Number of subjects: 19
Study 26308780 — intervention group
Group type: COMPARATOR
Intervention: Standard-care group (control)
Number of subjects: 19
Study 24436453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally applied tenofovir gel
Number of subjects: 0
Study 24436453 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22520693 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function analysis using thrombelastography
Number of subjects: 51
Study 22520693 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 51
Study 19023644 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MTP) 40 mg
Number of subjects: 24
Study 19023644 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (TMC) 40 mg
Number of subjects: 24
Study 17369514 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) feedback, focusing on arm joint movements
Number of subjects: 28
Study 17369514 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of Results (KR) feedback, focusing on movement precision
Number of subjects: 28
Study 17369514 — intervention group
Group type: COMPARATOR
Intervention: Nondisabled control group (n = 5) practicing the same task with KR
Number of subjects: 28
Study 15138948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospitals with multiple dissemination strategies for the Ottawa Ankle Rules (OARs)
Number of subjects: 4
Study 15138948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospitals with sequential directed education and personalized feedback strategies
Number of subjects: 4
Study 15138948 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 4
Study 10867040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g/d HPMC in 240 mL of orange drink taken between meals
Number of subjects: 51
Study 10867040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g/d HPMC in 240 mL of orange drink taken with meals
Number of subjects: 51
Study 9196770 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine/dapsone)
Number of subjects: 2000
Study 9196770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 8266770 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms per day sc.)
Number of subjects: 0
Study 8266770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2859136 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg) + Ethanol (800 to 950 mg/L)
Number of subjects: 6
Study 2859136 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Ethanol
Number of subjects: 6
Study 2859136 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam + Orange Juice
Number of subjects: 6
Study 3070032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (doses of 40 to 120 mg, twice daily for six weeks)
Number of subjects: 10
Study 3070032 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 10
Study 29670295 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest tertile of telomere length
Number of subjects: 2022
Study 28243132 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet in addition to allergy pharmacotherapy
Number of subjects: 992
Study 28243132 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus allergy pharmacotherapy
Number of subjects: 992
Study 26188211 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 8561
Study 26188211 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 8561
Study 23924555 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Strain Dophilus
Number of subjects: 14
Study 23924555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylak
Number of subjects: 14
Study 20298994 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg atorvastatin
Number of subjects: 171
Study 20298994 — intervention group
Group type: COMPARATOR
Intervention: 10-mg atorvastatin
Number of subjects: 171
Study 18206309 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice provided by health care practitioners (HCPs) for a vignette patient with non-specific low back pain (NSLBP)
Number of subjects: 1022
Study 18206309 — intervention group
Group type: EXPERIMENTAL
Intervention: Work advice related to Pain Attitudes and Beliefs Scale (PABS.PT) scores
Number of subjects: 1022
Study 16715326 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant flow insufflation of oxygen (CFIO) at a flow rate of 15 l/min
Number of subjects: 341
Study 16715326 — intervention group
Group type: COMPARATOR
Intervention: Standard endotracheal intubation and mechanical ventilation (MV)
Number of subjects: 341
Study 14507420 — intervention group
Group type: EXPERIMENTAL
Intervention: Education package applied to general practices
Number of subjects: 0
Study 14507420 — intervention group
Group type: COMPARATOR
Intervention: True endpoint data
Number of subjects: 0
Study 11115207 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care depression intervention
Number of subjects: 228
Study 11115207 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 228
Study 9109608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber (3, 4, or 7% of diet dry matter)
Number of subjects: 17
Study 9109608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber (TDF) and neutral detergent fiber (NDF)
Number of subjects: 17
Study 9109608 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical formula for predicting ME content
Number of subjects: 17
Study 8238158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 55
Study 8238158 — intervention group
Group type: COMPARATOR
Intervention: No oral tocolytic (Control)
Number of subjects: 55
Study 2930998 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine, 100 mg b.i.d.
Number of subjects: 75
Study 2930998 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline, 75 mg b.i.d.
Number of subjects: 75
Study 30837446 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) prior to high fidelity simulation training (HFS)
Number of subjects: 26
Study 30837446 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity simulation training (HFS) prior to problem-based learning (PBL)
Number of subjects: 26
Study 30837446 — intervention group
Group type: COMPARATOR
Intervention: Both methods (PBL prior to HFS and HFS prior to PBL)
Number of subjects: 26
Study 29629438 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Number of subjects: 30
Study 29629438 — intervention group
Group type: COMPARATOR
Intervention: Control (regular blood clot)
Number of subjects: 30
Study 27497358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 60
Study 27497358 — intervention group
Group type: COMPARATOR
Intervention: Metal drug-eluting stent (DES)
Number of subjects: 60
Study 25637563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual/triple-chamber ICDs
Number of subjects: 2790
Study 25637563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs
Number of subjects: 2790
Study 22927662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 153
Study 22927662 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 153
Study 21062484 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max estimated using the 2-km UKK walk test
Number of subjects: 427
Study 17696215 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery with BMI considered
Number of subjects: 488
Study 17696215 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery without considering BMI
Number of subjects: 488
Study 17409843 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin (CAR)
Number of subjects: 81
Study 17409843 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Cisplatin (CIS)
Number of subjects: 81
Study 14609832 — intervention group
Group type: EXPERIMENTAL
Intervention: Next Day Review (NDR)
Number of subjects: 362
Study 14609832 — intervention group
Group type: COMPARATOR
Intervention: Same Day Discharge (SDD)
Number of subjects: 362
Study 14609832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SDD and NDR)
Number of subjects: 362
Study 10672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Striper MFS
Number of subjects: 80
Study 10672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-Lex XT
Number of subjects: 80
Study 10672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance Composite Finishing and Polishing System
Number of subjects: 80
Study 10672147 — intervention group
Group type: EXPERIMENTAL
Intervention: Shofu Composite Finishing Kit
Number of subjects: 80
Study 9094272 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 201
Study 9094272 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 201
Study 8237933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg bid
Number of subjects: 37
Study 8237933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg bid
Number of subjects: 37
Study 8237933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg qid
Number of subjects: 37
Study 3535491 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 10 mg troches, three times per day
Number of subjects: 30
Study 3535491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31945779 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS) and high-perceived work stress
Number of subjects: 11875
Study 31945779 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese and non-smoking groups
Number of subjects: 11875
Study 29799810 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylate polymer
Number of subjects: 32
Study 29799810 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinylpyrrolidone (PVP) polymer
Number of subjects: 32
Study 29799810 — intervention group
Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 32
Study 26333529 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin treatment
Number of subjects: 1161
Study 26333529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study 23594784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 ppm fluoridated toothpaste
Number of subjects: 176
Study 23594784 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm fluoridated toothpaste
Number of subjects: 176
Study 20358155 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily for eight weeks
Number of subjects: 34
Study 20358155 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg once daily for eight weeks
Number of subjects: 34
Study 20358155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril 10 mg and losartan 50 mg daily for eight weeks
Number of subjects: 34
Study 17970793 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma volume expansion
Number of subjects: 172
Study 17970793 — intervention group
Group type: COMPARATOR
Intervention: No plasma volume expansion (Control)
Number of subjects: 172
Study 15911935 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular psychotherapeutic intervention for anxiety
Number of subjects: 2
Study 15911935 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2
Study 17016955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient-fortified beverage
Number of subjects: 0
Study 17016955 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 17016955 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic therapy
Number of subjects: 0
Study 10477530 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4, 8, or 16 mg)
Number of subjects: 768
Study 10477530 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 or 8 mg) plus 20 mg of enalapril
Number of subjects: 768
Study 10477530 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 768
Study 8698585 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly waived services from hospitals that received a capitated fee
Number of subjects: 0
Study 8698585 — intervention group
Group type: EXPERIMENTAL
Intervention: Services from providers who were paid fee-for-service
Number of subjects: 0
Study 8698585 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving waived services)
Number of subjects: 0
Study 1769411 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (bacillus Calmette‐Guérin + chemotherapy)
Number of subjects: 82
Study 1769411 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (bacillus Calmette‐Guérin alone)
Number of subjects: 82
Study 1769411 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (specifically for lower limb malignant melanoma)
Number of subjects: 82
Study 1769411 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (specifically for lower limb malignant melanoma)
Number of subjects: 82
Study 6280621 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined diet (whole foods, 60 g/day dietary fibre)
Number of subjects: 10
Study 6280621 — intervention group
Group type: COMPARATOR
Intervention: Refined diet (processed foods, 20 g/day dietary fibre)
Number of subjects: 10
Study 31342097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 15
Study 31342097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28709832 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative roommate with dissimilar surgical status (TKA)
Number of subjects: 520
Study 28709832 — intervention group
Group type: COMPARATOR
Intervention: Postoperative roommate with similar surgical status (TKA)
Number of subjects: 520
Study 25543977 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability shoe
Number of subjects: 14
Study 25543977 — intervention group
Group type: COMPARATOR
Intervention: Neutral shoe with prefabricated orthoses
Number of subjects: 14
Study 25543977 — intervention group
Group type: COMPARATOR
Intervention: Neutral shoe
Number of subjects: 14
Study 25543977 — intervention group
Group type: COMPARATOR
Intervention: Neutral shoe with customised orthoses
Number of subjects: 14
Study 24598949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation
Number of subjects: 28
Study 24598949 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation with T-tube
Number of subjects: 28
Study 21765354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Number of subjects: 40
Study 21765354 — intervention group
Group type: COMPARATOR
Intervention: Case-based learning
Number of subjects: 40
Study 19457248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNB‐1b)
Number of subjects: 468
Study 19457248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 16750497 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ADT
Number of subjects: 98
Study 16750497 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 98
Study 15171560 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 7
Study 11586056 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 mg)
Number of subjects: 12
Study 11586056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9202918 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural alkalinized lignocaine
Number of subjects: 32
Study 9202918 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid hyperbaric bupivacaine
Number of subjects: 32
Study 7768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of dofetilide (0.5 mg over 30 minutes)
Number of subjects: 10
Study 7768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of dofetilide (0.5 mg)
Number of subjects: 10
Study 7768076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of dofetilide (0.5 mg)
Number of subjects: 10
Study 2213375 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance fluid requirements plus replacement of any deficit (mean of 1.42 times calculated maintenance fluid requirements)
Number of subjects: 19
Study 2213375 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction to two thirds of maintenance requirements (mean of 0.65 times maintenance)
Number of subjects: 19
Study 496237 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine mixed with dextran 40 solution
Number of subjects: 40
Study 496237 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 40
Study 31841570 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious affiliation (older women ≥65 years)
Number of subjects: 7524
Study 31841570 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in religious activities more than once per week (older women ≥65 years)
Number of subjects: 7524
Study 31841570 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly religious activities
Number of subjects: 7524
Study 31841570 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive episode (MDE) prevalence
Number of subjects: 7524
Study 28299455 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300 mg twice a day for 60 days
Number of subjects: 61
Study 28299455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (exactly the same appearance as PEA) every 12 hours for 60 days
Number of subjects: 61
Study 26428224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin in addition to conservative treatment
Number of subjects: 40
Study 26428224 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 40
Study 25455116 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-focused intervention (educational sessions, electronic health record-based alerts, and performance feedback)
Number of subjects: 17016
Study 25455116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (clinician-focused + family-focused)
Number of subjects: 17016
Study 25455116 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused intervention (automated educational phone calls)
Number of subjects: 17016
Study 25455116 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 17016
Study 22169269 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (74 Gy in 37 fractions of 2 Gy)
Number of subjects: 457
Study 22169269 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated treatment (60 Gy in 20 fractions of 3 Gy)
Number of subjects: 457
Study 22169269 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated treatment (57 Gy in 19 fractions of 3 Gy)
Number of subjects: 457
Study 21058472 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling therapy (local and distal points and points selection according to the differentiation)
Number of subjects: 36
Study 21058472 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular electroacupuncture therapy
Number of subjects: 36
Study 21058472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting at Taiyang Zimai (Extra) or Taiyang (EX‐HN 5) and Ashi points
Number of subjects: 36
Study 17047932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 8
Study 17047932 — intervention group
Group type: COMPARATOR
Intervention: MDMA 1.5 mg/kg
Number of subjects: 8
Study 17047932 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 1.5 mg/kg with Fluoxetine 20 mg
Number of subjects: 8
Study 16143048 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg orally
Number of subjects: 51
Study 16143048 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg rectally
Number of subjects: 51
Study 16143048 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/kg rectally
Number of subjects: 51
Study 16143048 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal high-dose (35 mg/kg)
Number of subjects: 51
Study 12490213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhizophora mangle aqueous bark extract (once a day)
Number of subjects: 37
Study 12490213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhizophora mangle aqueous bark extract (twice a day)
Number of subjects: 37
Study 12490213 — intervention group
Group type: COMPARATOR
Intervention: mercurocrome (twice a day)
Number of subjects: 37
Study 9009112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK-OP) 30 ng/kg stat and 60 ng/kg/hr by infusion
Number of subjects: 16
Study 9009112 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.01 mg/kg stat and 0.01 mg/kg/hr by infusion
Number of subjects: 16
Study 8363688 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorthand vertical mattress sutures
Number of subjects: 30
Study 8363688 — intervention group
Group type: COMPARATOR
Intervention: Classic vertical mattress sutures
Number of subjects: 30
Study 3107289 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropic releasing hormone (TRH)
Number of subjects: 60
Study 3107289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29499742 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiltse's paraspinal approach (group A)
Number of subjects: 47
Study 29499742 — intervention group
Group type: COMPARATOR
Intervention: Open book laminectomy (group B)
Number of subjects: 47